Much regulatory progress in Japan but more needed - PhRMA
This article was originally published in Scrip
Progress in the regulatory area in Japan in recent years has helped to speed up new product approvals and encourage participation in multinational clinical trials, but further improvements are needed in a number of areas, the US research-based industry association PhRMA maintains.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.